Mirion Lifts Sales Outlook, Cuts Top Of EBITDA Range To $292 Million From $300 Million

Third-quarter revenue rose 24.5% to $277.8 million, and the company raised its cash flow outlook as it narrowed profit ranges.

Share
Mirion Lifts Sales Outlook, Cuts Top Of EBITDA Range To $292 Million From $300 Million

Mirion Technologies, which makes radiation detection and monitoring products, raised its 2026 revenue growth outlook to about 24%-25% from 22%-24% but lowered the top of its adjusted EBITDA range to $292 million from $300 million, according to its third-quarter results on Tuesday. Third-quarter revenue rose 24.5% to $277.8 million from $223.1 million a year earlier.

Orders jump, margins slip

Net income was $7.8 million, or $0.03 a share, against $3.1 million, or $0.01, a year earlier. Adjusted earnings per share was flat at $0.12, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, with adjustments) rose to $64.8 million from $52.4 million. The adjusted EBITDA margin slipped to 23.3% from 23.5%.

Orders excluding the Paragon and Certrec acquisitions were $340 million, up 62% from $209 million. Including them, orders were $386 million, up 85%.

Chairman and CEO Thomas Logan said orders were "boosted by a 105% increase in nuclear power-related orders." Organic revenue, which strips out currency and acquisitions, rose 6.5%.

Guidance moves in both directions

The company revised several 2026 targets:

  • Organic revenue growth of about 7%-8%, from 5%-7%.
  • Adjusted EBITDA of about $285 million-$292 million, from $285 million-$300 million.
  • Adjusted free cash flow of about $170 million-$185 million, from $155 million-$175 million.
  • Adjusted EPS of about $0.50-$0.54, from $0.48-$0.55.

Logan said the company was updating guidance "to reflect increased visibility to full year performance." He said he expects mid-to-high teens organic growth in the fourth quarter.

Cash flow and the nuclear fleet

Adjusted free cash flow was $47 million in the quarter and $107 million for the first nine months, which Logan described as a doubling. He said net leverage should fall to about 2.6x by year-end.

Mirion sells to nuclear power plants, labs and defense customers, and its Medical segment sells cancer care quality assurance tools and dosimetry services. Logan said the company has a presence in over 98% of commercial nuclear plants globally, and that approximately 80% of its nuclear power-related revenue comes from reactors operating today.

Mirion hosts a conference call on Wednesday at 10:00 a.m. ET to discuss the results and the revised 2026 forecast.

Sources